From Bloomberg about Pfizer's TTR drug.
At about 2/3 of the way through the article, mention is made of ALNY's and Isis' TTR drugs in development.
Excerpts from article:
"Pfizer’s pill targets transthyretin, a protein which carries thyroid hormone and retinol. In those with the rare genetic mutation that causes TTR-FAP, the protein breaks apart and clumps into plaques called amyloids. "
"The current treatment is a liver transplant -- the organ produces the problematic protein and a new one can extend patients’ lives. Alnylam Pharmaceuticals Inc. (ALNY), based in Cambridge, Massachusetts, also has a drug in early trials. Isis Pharmaceuticals Inc. (ISIS), based in Carlsbad, California, and London-based GlaxoSmithKline Plc (GSK) have teamed to develop a treatment.
Analysts haven’t estimated a market for the medicines. Pfizer declined to comment on its European or potential U.S. sales.
The Alnylam and Isis therapies stop the production of the transthyretin protein, said Rodney Falk, director of Brigham and Women’s Hospital’s program for cardiac amyloidosis, a related disease where patients’ heart muscles are damaged. The hospital is based in Boston.
“I don’t think they’re necessary rivals to tafamidis,”Falk said in a phone interview. “My prediction is that none of these drugs will be perfect, and we’ll end up using a combination.” "